Inhibition of the programmed death-1 (PD-1)/programmed-ligand 1 (PD-L1) axis with immune control point inhibitors (ICPI), including nivolumab, avelumab and pembrolizumab, has emerged as new therapeutical strategy for GC patients. This evidence concerns the gene CD274 and gastric cancer.